SOX9 and cancer: These numbers are in the upper range of earlier immunohistochemistry studies reporting 41–55% SOX9 positive cancers by conventional large section analysis involving up to 36 tumors [11,16], or of TMA studies reporting 46–100% SOX9 positivity in up to 387 prostate cancers [10,14,17].